These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 18980019)

  • 1. Synergistic effect of 5-Aza-2'-deoxycytidine and genistein in combination against leukemia.
    Raynal NJ; Charbonneau M; Momparler LF; Momparler RL
    Oncol Res; 2008; 17(5):223-30. PubMed ID: 18980019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancement of antineoplastic action of 5-aza-2'-deoxycytidine by zebularine on L1210 leukemia.
    Lemaire M; Momparler LF; Bernstein ML; Marquez VE; Momparler RL
    Anticancer Drugs; 2005 Mar; 16(3):301-8. PubMed ID: 15711182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement of antineoplastic action of 5-aza-2'-deoxycytidine by phenylbutyrate on L1210 leukemic cells.
    Lemaire M; Momparler LF; Farinha NJ; Bernstein M; Momparler RL
    Leuk Lymphoma; 2004 Jan; 45(1):147-54. PubMed ID: 15061212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological approach for optimization of the dose schedule of 5-Aza-2'-deoxycytidine (Decitabine) for the therapy of leukemia.
    Momparler RL; Côté S; Eliopoulos N
    Leukemia; 1997 Feb; 11(2):175-80. PubMed ID: 9009076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the antileukemic activity of 5-AZA-2'-deoxycytidine, 1-beta-D-arabinofuranosylcytosine and 5-azacytidine against L1210 leukemia.
    Momparler RL; Momparler LF; Samson J
    Leuk Res; 1984; 8(6):1043-9. PubMed ID: 6083417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 3-Deazauridine enhances the antileukemic action of 5-aza-2'-deoxycytidine and targets drug-resistance due to deficiency in deoxycytidine kinase.
    Raynal NJ; Momparler LF; Rivard GE; Momparler RL
    Leuk Res; 2011 Jan; 35(1):110-8. PubMed ID: 20510451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical evaluation of antineoplastic activity of inhibitors of DNA methylation (5-aza-2'-deoxycytidine) and histone deacetylation (trichostatin A, depsipeptide) in combination against myeloid leukemic cells.
    Shaker S; Bernstein M; Momparler LF; Momparler RL
    Leuk Res; 2003 May; 27(5):437-44. PubMed ID: 12620295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic antileukemic action of a combination of inhibitors of DNA methylation and histone methylation.
    Momparler RL; Idaghdour Y; Marquez VE; Momparler LF
    Leuk Res; 2012 Aug; 36(8):1049-54. PubMed ID: 22472464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 5-aza-2'-deoxycytidine therapy in patients with acute leukemia inhibits DNA methylation.
    Momparler RL; Bouchard J; Onetto N; Rivard GE
    Leuk Res; 1984; 8(2):181-5. PubMed ID: 6201685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy of L1210 and L1210/ARA-C leukemia with 5-aza-2'-deoxycytidine and 3-deazauridine.
    Momparler RL; Momparler LF
    Cancer Chemother Pharmacol; 1989; 25(1):51-4. PubMed ID: 2480188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of antineoplastic activity of cytosine arabinoside and 5-aza-2'-deoxycytidine against human leukemic cells of different phenotype.
    Momparler RL; Onetto-Pothier N; Momparler LF
    Leuk Res; 1990; 14(9):755-60. PubMed ID: 1700231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combinational chemotherapy of L1210 and L1210/ARA-C leukemia with 5-AZA-2'-deoxycytidine and beta-2'-deoxythioguanosine.
    Momparler RL; Momparler LF; Samson J
    Int J Cancer; 1982 Sep; 30(3):361-64. PubMed ID: 6182115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of 5-aza-2'-deoxycytidine and interferon-alpha on differentiation and oncogene expression in HL-60 myeloid leukemic cells.
    Doré BT; Momparler RL
    Anticancer Drugs; 1992 Jun; 3(3):281-7. PubMed ID: 1381972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of cytidine deaminase in HL-60 myeloid leukemic cells by 5-aza-2'-deoxycytidine.
    Momparler RL; Laliberté J
    Leuk Res; 1990; 14(9):751-4. PubMed ID: 1700230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Studies on the mechanism of the synergistic interaction between 2'-deoxy-5-azacytidine and cisplatin.
    Abbruzzese JL; Frost P
    Cancer Chemother Pharmacol; 1992; 30(1):31-6. PubMed ID: 1375133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological approach for optimization of the dose schedule of 5-Aza-2'-deoxycytidine (Decitabine) for the therapy of leukemia.
    Momparler RL; Côté S; Eliopoulos N
    Leukemia; 1997 Mar; 11 Suppl 1():S1-6. PubMed ID: 9130684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Importance of dose-schedule of 5-aza-2'-deoxycytidine for epigenetic therapy of cancer.
    Lemaire M; Chabot GG; Raynal NJ; Momparler LF; Hurtubise A; Bernstein ML; Momparler RL
    BMC Cancer; 2008 May; 8():128. PubMed ID: 18454857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacology of 5-Aza-2'-deoxycytidine (decitabine).
    Momparler RL
    Semin Hematol; 2005 Jul; 42(3 Suppl 2):S9-16. PubMed ID: 16015507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interaction of 5-aza-2'-deoxycytidine with amsacrine or 1,25-dihydroxyvitamin D3 on HL-60 myeloid leukemic cells and inhibitors of cytidine deaminase.
    Momparler RL; Doré BT; Labiberté J; Momparler LF
    Leukemia; 1993 May; 7 Suppl 1():17-20. PubMed ID: 7683351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiproliferative effects and DNA hypomethylation by 5-aza-2'-deoxycytidine in human neuroblastoma cell lines.
    Carpinelli P; Granata F; Augusti-Tocco G; Rossi M; Bartolucci S
    Anticancer Drugs; 1993 Dec; 4(6):629-35. PubMed ID: 7507741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.